The rise and fall

Currently Playing: The rise and fall of 23andMe

MasterClass Executive is designed to help professionals build real skills, demonstrate their thinking, and develop work that shows what they’re capable of. Sign up today for free at https://masterclass.yt.link/f9nw03o What happened to 23andMe? This business breakdown explores the rise and fall of 23andMe, one of the most ambitious biotech startups of the 21st century. Get the 2-minute cheat sheet for this video → https://girdley.com/youtube 👇 SUBSCRIBE for more business breakdowns https://www.youtube.com/@Michael-Girdley?sub_confirmation=1 ------------------------------------------------------------------ ► Get my weekly letter to business owners: essential insights to run, grow, and stay ahead in your business → https://links.girdley.com/newsletter-yt ► For sponsorships or inquiries please reach out to: Contact@girdley.com ► Do you have a hat I should wear in a video? Send it to us: Contact@girdley.com ► Free events on all things small business: https://links.girdley.com/lectures-yt ► Deep dives on businesses for sale: https://www.youtube.com/@AcquisitionsAnonymousPodcast ► Follow me on Twitter/X: https://x.com/girdley ------------------------------------------------------------------ Founded in 2006 by Anne Wojcicki, 23andMe set out to revolutionize healthcare by giving consumers direct access to their genetic data. The idea was simple: spit in a tube, send it to a lab, and receive insights about your ancestry and health risks. The concept quickly gained traction, earning recognition as Time’s “Invention of the Year” and backing from major players like Google and GlaxoSmithKline. But the rise of 23andMe was anything but smooth. In 2013, the FDA issued a cease and desist order, forcing the company to halt key parts of its product due to unverified health claims. What followed was a multi-year regulatory battle, with over 7,000 pages of evidence submitted before the company regained approval. As the company rebuilt, it shifted its focus toward drug discovery, leveraging one of the largest genetic databases in the world. This move attracted a $300 million partnership with GlaxoSmithKline and fueled the narrative that 23andMe could become a biotech powerhouse. Then came the SPAC boom. In 2021, 23andMe went public through a deal backed by Richard Branson, reaching a peak valuation of over $6 billion. But underneath the hype, fundamental problems remained. The company struggled with a weak business model based on one-time purchases, rising customer acquisition costs, and no consistent revenue stream. The turning point came in 2023 with a massive data breach that exposed genetic information from millions of users. The company’s response further damaged trust, accelerating its decline. Partnerships unraveled, revenue dropped, and losses mounted. By 2025, 23andMe filed for bankruptcy. A company once valued in the billions was reduced to less than $20 million. In a controversial twist, Anne Wojcicki reacquired the company’s assets, including its vast genetic database, raising new concerns about data ownership and privacy. This 23andMe documentary examines the full story—from groundbreaking innovation to regulatory battles, failed monetization, and ultimate collapse. It’s a case study in hype versus fundamentals, and a reminder that even revolutionary ideas need sustainable business models.